Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOTRICITY INC.BTCY · Entity 8507 | Director | March 12, 2023 | March 15, 2023 |
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director | February 14, 2025 | February 19, 2025 |
| Healthcare Triangle, Inc.HCTI · Entity 7909 | Director | March 12, 2024 | March 13, 2024 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Director · CEO & President | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOTRICITY INC.
Report date March 12, 2023 · Filed March 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2028-03-12 | Direct | 474,683 |
Reported balance
After 2023-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-12 · Grant · Acquired 75,930 · Balance 474,683 F1: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting.
BioRestorative Therapies, Inc.
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 52,632 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Grant · Acquired 52,632 · Balance 52,632 F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing every month thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 10,490 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 10,490 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 32,028 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 32,028 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 79,646 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 79,646 F1: The option is currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing every month thereafter until fully vested.
Healthcare Triangle, Inc.
Report date March 12, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2029-03-12 | Direct | 34,000 |
Reported balance
After 2024-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-12 · Grant · Acquired 10,000 · Balance 34,000 F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 10,000 options vesting immediately. F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.
F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 10,000 options vesting immediately.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2036-08-27 | Direct | 68,000 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 68,000 · Balance 68,000 F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2021 Filed Nov 8, 2021 22:42 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,490 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019510 · doc1.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal, quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 10:04 UTC | BIOTRICITY INC. BTCY · Entity 8507 | SaleCommon Stock | 3,318 | $3.05 | $10,119.90 |
DisclosureSEC source: 0001493152-21-025255 · ownership.xml · nonDerivative · entry 3 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · shares: The shares were issued pursuant to the Company's 2016 Equity Incentive Plan. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 10:04 UTC | BIOTRICITY INC. BTCY · Entity 8507 | SaleCommon Stock | 9,481 | $3.20 | $30,333.51 |
DisclosureSEC source: 0001493152-21-025255 · ownership.xml · nonDerivative · entry 2 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,318 F1 · shares: The shares were issued pursuant to the Company's 2016 Equity Incentive Plan. Read SEC document |
| October 07, 2021 Filed Oct 13, 2021 10:04 UTC | BIOTRICITY INC. BTCY · Entity 8507 | SaleCommon Stock | 17,228 | $3.08 | $53,119.09 |
DisclosureSEC source: 0001493152-21-025255 · ownership.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,799 F1 · shares: The shares were issued pursuant to the Company's 2016 Equity Incentive Plan. Read SEC document |
| September 16, 2021 Filed Sep 29, 2021 22:36 UTC | BIOTRICITY INC. BTCY · Entity 8507 | SaleCommon Stock | 34,977 | $3.43 | $119,915.15 |
DisclosureSEC source: 0001493152-21-024126 · ownership.xml · nonDerivative · entry 2 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,027 F1 · shares: The shares were issued pursuant to the Company's 2016 Equity Incentive Plan. Read SEC document |
| September 15, 2021 Filed Sep 29, 2021 22:36 UTC | BIOTRICITY INC. BTCY · Entity 8507 | SaleCommon Stock | 6,246 | $3.27 | $20,421.30 |
DisclosureSEC source: 0001493152-21-024126 · ownership.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,004 F1 · shares: The shares were issued pursuant to the Company's 2016 Equity Incentive Plan. Read SEC document |
| May 26, 2021 Filed Oct 7, 2021 20:03 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 83,333 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001540354-21-000001 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,667 Underlying: Common Stock · 83,333 shares Expires 2031-01-27 F1 · derivative.exercise_date: On January 27, 2021, the reporting person was granted an option to purchase shares of common stock, 83,333 shares of which were subject to performance criteria, which performance criteria were met on May 26, 2021, resulting in the vesting of that portion of the option. Read SEC document |
| March 21, 2021 Filed Sep 9, 2022 22:36 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to buy) · Derivative | 31,106 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-22-025543 · ownership.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,753 Underlying: Common Stock · 31,106 shares Expires 2031-03-31 F1 · derivative.exercise_date: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:49 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 1,000,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001596771-21-000005 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: 25% will vest on January 27, 2022 and the remaining will vest in 36 equal monthly installments on the last day of each month beginning on February 28, 2022. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 21:08 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to purchase) · Derivative | 367,647 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-20-006128 · ownership.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,647 Underlying: Common Stock · 367,647 shares Expires 2030-04-07 F1 · price: Granted in connection with the Reporting Person's service on the Company's board. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:32 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001596771-19-000134 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-11-05 F1 · derivative.exercise_date: 25% will vest on November 5, 2020 and the remaining 75% will vest in 36 equal monthly installments beginning on December 1, 2020. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 20:28 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp OSOK · Entity 7808 | GrantCommon Stock | 793,822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-17-000064 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,822 F1 · price: The reporting person acquired the shares of NeuroOne Medical Technologies Corporation ("NMTC") on July 20, 2017, in exchange for shares of common stock of NeuroOne, Inc. ("NeuroOne"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2017, between NMTC, OSOK Acquisition Company and NeuroOne, pursuant to which NeuroOne became the wholly-owned subsidiary of NMTC. Per the terms of the Merger Agreement, each share of NeuroOne common stock was converted into the right to receive 17.0103706 shares of NMTC common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.